Capital Stock (Details) - USD ($)						3 Months Ended
Capital Stock (Details) - USD ($)	Mar. 03, 2026	Mar. 02, 2026	Feb. 25, 2026	Feb. 19, 2026	Feb. 13, 2026	Mar. 31, 2026	Mar. 31, 2025	Feb. 09, 2026	Dec. 31, 2025	Nov. 17, 2025
Stockholders’ Equity [Line Items]
Shares issued						10,442,960			5,442,249
Conversion price (in Dollars per share)										$ 11.42
Purchase price (in Dollars)								$ 250,000		$ 4,750
Minimum purchase amount (in Dollars)				$ 250,000
Offering costs (in Dollars)						$ 762,574
Owning shares						250
Unfunded commitment amount (in Dollars)						$ 0
Closing period						3 years
Trading days					10 days
Cumulative dividends earned (in Dollars)						$ 54,192
Percentage of weighed average price					89.00%
Percentage of floor price					20.00%
Percentage of redeemed					120.00%
Common stock and outstanding						10,442,960			5,442,249
Dividend yield, percentage						0.00%
Volatility, percentage						79.40%
Estimated term						6 years 21 days
Stock-based compensation (in Dollars)						$ 128,440	129,650
Unrecognized share-based compensation (in Dollars)						$ 1,274,285
Unvested stock options peried						4 years
Cost of Revenues [Member]
Stockholders’ Equity [Line Items]
Stock-based compensation (in Dollars)						$ 4,657	4,657
Sales General and Administrative Expenses [Member]
Stockholders’ Equity [Line Items]
Stock-based compensation (in Dollars)						98,379	99,589
Research and Development [Member]
Stockholders’ Equity [Line Items]
Stock-based compensation (in Dollars)						$ 25,404	$ 25,404
Convertible Promissory Notes [Member]
Stockholders’ Equity [Line Items]
Shares issued			91,535	14,151
Accrued interest (in Dollars)			$ 760,955	$ 73,857
Two Thousand Twenty Two Stock Incentive Plan [Member]
Stockholders’ Equity [Line Items]
Shares purchased	352,936
Exercise price (in Dollars per share)	$ 3.39
Vest over term of one year	4 years
Common Stock [Member]
Stockholders’ Equity [Line Items]
Shares issued				173,505		10,442,960			5,442,249
Percentage of beneficially own excess shares					9.99%
Conversion shares				846,368
Number of shares issued for service		4,193				4,193
Common stock and outstanding						10,442,960			5,442,249
Common Stock [Member] \| Warrant [Member]
Stockholders’ Equity [Line Items]
Warrant to purchase shares				3,502,627
Exercise price (in Dollars per share)				$ 11.42
Purchase price (in Dollars)				$ 5,000,000
Common Stock Upon the Conversion of Series A Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Conversion shares				846,368
Common Stock Upon Conversion of Series A-1 Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Conversion shares				651,465
Common Stock Upon Conversion of Series A-2 Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Conversion shares				442,402
Common Stock Upon Conversion of Series B Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Conversion shares				1,471,487
Common Stock Upon the Conversion of Series C Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Conversion shares				1,204,040
Common Stock Upon the Conversion of Series D Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Conversion shares				101,565
Maxim Placement Agent Services [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)				$ 13.704				$ 8.16
Number of warrant to purchase				24,057				2,022
Warrant term				5 years				5 years
Stock Options [Member]
Stockholders’ Equity [Line Items]
Dividend yield, percentage						0.00%
Volatility, percentage						79.40%
Estimated term						6 years
Total fair market value (in Dollars)						$ 712,715
Streeterville Pursuant to Note Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)								$ 8
Number of warrant to purchase								62,500
Streeterville Pursuant to Preferred Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)				$ 11.42
Number of warrant to purchase				3,502,627
Series E Convertible Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Share value (in Dollars)										$ 40,000,000
Purchase price (in Dollars per share)										$ 1,000
Conversion price (in Dollars per share)					$ 11.42
Shares issued				5,000
Purchase price (in Dollars per share)				$ 1,000
Maximum purchase amount (in Dollars)				$ 40,000,000
Gross proceeds (in Dollars)				5,000,000
Offering costs (in Dollars)				$ 4,416,631
Number of designated shares.					45,000
Stated value (in Dollars)					$ 1,098.9
Percentage of stated value					10.00%
Annual rate					15.00%
Trading days					5 days
Cumulative dividends earned (in Dollars)						$ 54,192
Days after issuance days					6 months
Convertible preferred stock issued						5,000			0
Convertible preferred stock outstanding						5,000			0
Series E Convertible Preferred Stock [Member] \| Dividend Rights [Member]
Stockholders’ Equity [Line Items]
Percentage of stated value					9.00%
Commitment Shares [Member] \| Common Stock [Member]
Stockholders’ Equity [Line Items]
Shares issued										50,000
Pre-Delivery Shares [Member]
Stockholders’ Equity [Line Items]
Purchase price (in Dollars per share)						$ 0.01
Pre-Delivery Shares [Member] \| Common Stock [Member]
Stockholders’ Equity [Line Items]
Shares issued										475,000
Series A-1 preferred stock [Member]
Stockholders’ Equity [Line Items]
Share value (in Dollars)									$ 6,515
Shares issued						0			651,465
Conversion shares				651,465
SeriesA-2 Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Share value (in Dollars)									$ 4,424
Shares issued						0			442,402
Conversion shares				442,402
Series B Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Share value (in Dollars)									$ 14,715
Shares issued						0			1,471,487
Conversion shares				1,471,487
Series C Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Share value (in Dollars)									$ 12,040
Shares issued						0			1,204,040
Conversion shares				1,204,040
Series D Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Share value (in Dollars)									$ 1,016
Shares issued						0			101,565
Conversion shares				101,565

20/20 Biolabs, Inc. 10-Q